Vir Biotechnology, Inc.
Clinical trials sponsored by Vir Biotechnology, Inc., explained in plain language.
A clinical-stage immunology company focused on infectious diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New hope for tough prostate cancer: first human trial of VIR-5500 begins
Disease control Recruiting nowThis early-stage study tests a new drug called VIR-5500 in people with advanced prostate cancer that has stopped responding to hormone treatment. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors or lower PSA levels. …
Phase: PHASE1 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New cancer drug VIR-5525 enters first human trials for EGFR-Positive tumors
Disease control Recruiting nowThis early-stage study tests a new drug called VIR-5525, alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have a protein called EGFR. The main goals are to check safety and find the right dose. About 450 adults with tumors that cannot b…
Phase: PHASE1 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug combo targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called VIR-5818, alone or combined with the immunotherapy pembrolizumab, in people with advanced HER2-expressing cancers that have not responded to standard treatments. The study will first find the safest dose, then expand to see if t…
Phase: PHASE1, PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC